A. Białas

发表

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

M. Mikuła, J. Ostrowski, A. Wróbel, 2017, Oncotarget.

N-substituted aminomethanephosphonic and aminomethane-P-methylphosphinic acids as inhibitors of ureases

Paulina Kosikowska, Łukasz Berlicki, P. Kafarski, 2011, Amino Acids.

N-substituted aminomethanephosphonic and aminomethane-P-methylphosphinic acids as inhibitors of ureases

Paulina Kosikowska, Łukasz Berlicki, P. Kafarski, 2011, Amino Acids.

Exploring the Sn binding pockets in gingipains by newly developed inhibitors: structure-based design, chemistry, and activity.

J. Otlewski, J. Grembecka, J. Potempa, 2006, Journal of medicinal chemistry.

Discovery and Structure–Activity Relationships of N‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors

M. Jurzak, M. Nowak, M. Kujawa, 2018, ChemMedChem.

Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties.

M. Jurzak, M. Nowak, M. Kujawa, 2019, Bioorganic & medicinal chemistry letters.

Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.

M. Jurzak, M. Nowak, M. Kujawa, 2018 .

Development and characterization of a new inhibitor of heme oxygenase activity for cancer treatment.

Bożena Szelążek, P. Grudnik, G. Dubin, 2019, Archives of biochemistry and biophysics.

Proteases as anti-cancer targets--molecular and biological basis for development of inhibitor-like drugs against cancer.

P. Kafarski, A. Białas, 2009, Anti-cancer agents in medicinal chemistry.

Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 4

M. Nowak, M. Mikulski, H. Eggenweiler, 2019 .